laquinimod
Small moleculeexperimental
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease. — Wikipedia
Clinical trial activity
17 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
14
Phase 3
6
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00349193)
Timeline
Indications
Studied for
- Crohn Disease · Phase 2
- Eye Diseases · Phase 1
- Huntington Disease · Phase 2
- Inflammation · Phase 1
- Lupus Erythematosus, Systemic · Phase 2
- Lupus Nephritis · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Multiple Sclerosis · Phase 3
- Multiple Sclerosis, Chronic Progressive · Phase 2
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Pharmacokinetics · Phase 1
- Uveitis · Phase 1
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1- Mol. weight
- 356.81 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL66092 ↗
- WikipediaLaquinimod ↗
- ChEMBLCHEMBL2103814 ↗
Also known as
- abr215062
- abr 215062
- abr-215062
- abr-215062 sodium
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod
- laquinimod sodium
- saik-ms
- tv-5600
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06161415 | Phase 1 | Jan 31, 2024 | Global Ophthalmic Research Center (GORC), Stanford University |
| NCT05187403 | Phase 1 | Dec 9, 2021 | Active Biotech AB, Medical University of Vienna |
| NCT02284568 | Phase 2 | Jan 1, 2015 | Teva |
| NCT02215616 | Phase 2 | Nov 30, 2014 | Teva |
| NCT02085863 | Phase 1 | Feb 1, 2014 | Teva |
| NCT01975298 | Phase 3 | Jan 1, 2014 | Teva |
| NCT01707992 | Phase 3 | Feb 28, 2013 | Teva |
| NCT01404117 | Phase 2 | Mar 1, 2012 | Teva |
| NCT01085097 | Phase 2 | Jul 1, 2010 | Teva, University of Cambridge |
| NCT01085084 | Phase 2 | Jul 1, 2010 | Teva, University of California, San Francisco |
| NCT00737932 | Phase 2 | May 1, 2010 | Imelda Hospital, Bonheiden, Teva |
| NCT01047319 | Phase 3 | Apr 1, 2010 | Teva, University of Colorado, Denver |
| NCT00988052 | Phase 3 | Nov 1, 2009 | Teva |
| NCT00605215 | Phase 3 | Apr 1, 2008 | Teva, University of Arizona |
| NCT00509145 | Phase 3 | Dec 1, 2007 | Teva |
| NCT00745615 | Phase 2 | Dec 1, 2006 | Teva, Vita-Salute University of Milano. Italy |
| NCT00349193 | Phase 2 | Mar 1, 2005 | Teva |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 15 | 15 | 3 | 2005 |
| Active Biotech AB | For profit | 1 | 1 | 1 | 2021 |
| Global Ophthalmic Research Center (GORC) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Imelda Hospital, Bonheiden | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 0 | 1 | 2006 |
11 organizations
Page 1 / 1